Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

The injectable drug Ozempic is shown Saturday ... The 503As, however, could exploit a loophole: They can still make semaglutide copies that are not "essential copies" of the drug.

Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...

The 503As, however, could exploit a loophole: They can still make semaglutide ... that is not identical or nearly identical to Ozempic and Wegovy. While the FDA allows this, it also warns on ...

The 503As, however, could exploit a loophole: They can still make semaglutide copies that are not "essential copies" of the drug. That means they can make a version of semaglutide that is not ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...